Skip to main content

Table 4 In-hospital mortality in patients with community acquired severe sepsis at Haukeland University Hospital in 2008

From: Aetiology, antimicrobial therapy and outcome of patients with community acquired severe sepsis: a prospective study in a Norwegian university hospital

 

Alla

Non-survivors

Unadjusted models

Fully adjusted modelb

Final modelc

Characteristic

n

n

(%)

OR

95% CI

P value

OR

95% CI

P value

OR

95% CI

P value

Gender

     

0.240

      

 Male

117

33

(28.2)

1.00

Reference

       

 Female

103

22

(21.4)

0.69

(0.37, 1.29)

       

Age (years)

     

0.065

  

0.619

   

 16-30

18

1

(5.6)

1.00

Reference

 

1.00

Reference

    

 30-45

22

4

(18.2)

3.78

(0.38, 37.28)

 

0.99

(0.07, 14.18)

    

 45-60

36

8

(22.2)

4.86

(0.56, 42.30)

 

2.27

(0.19, 26.64)

    

 60-75

68

16

(23.5)

5.23

(0.65, 42.43)

 

2.88

(0.28, 29.54)

    

 ≥75

76

26

(34.2)

8.84

(1.11, 70.18)

 

3.09

(0.28, 33.54)

    

Comorbidity

            

 None

23

1

(4.3)

0.12

(0.02, 0.92)

0.005

      

 Hypertension

91

18

(19.8)

0.61

(0.32, 1.17)

0.130

      

 Cardiovascular

107

35

(32.7)

2.26

(1.20, 4.24)

0.010

2.18

(0.85, 5.61)

0.101

3.29

(1.45, 7.48)

0.003

 Pulmonary

61

14

(23.0)

0.86

(0.43, 1.72)

0.662

      

 Diabetes

38

9

(23.7)

0.92

(0.40, 2.08)

0.836

      

 Malignancy

31

13

(41.9)

2.53

(1.15, 5.58)

0.025

5.97

(1.96, 18.19)

0.001

5.50

(1.92, 15.78)

0.001

 Dementia

17

6

(35.3)

1.71

(0.60, 4.88)

0.324

      

 Psychiatric

51

9

(17.6)

0.57

(0.26, 1.27)

0.155

      

 Substance abuse

31

6

(19.4)

0.69

(0.27, 1.77)

0.423

      

 Otherd

74

27

(36.5)

2.42

(1.29, 4.53)

0.006

2.52

(1.11, 5.70)

0.025

2.43

(1.10, 5.35)

0.026

Correct suspected focus of infection

     

0.020

  

0.606

   

 Yes

152

31

(20.4)

1.00

Reference

 

1.00

Reference

    

 No

68

24

(35.3)

2.13

(1.13, 4.02)

 

0.79

(0.33, 1.91)

    

Confirmed focus of infection

     

0.007

  

0.003

  

0.001

 Respiratory

115

25

(21.7)

1.00

Reference

 

1.00

Reference

    

 Genitourinary

31

4

(12.9)

0.53

(0.17, 1.67)

 

0.41

(0.08, 2.21)

 

0.47

(0.09, 2.39)

 

 Soft tissue

27

6

(22.2)

1.03

(0.38, 2.82)

 

2.04

(0.55, 7.60)

 

2.42

(0.68, 8.68)

 

 Abdominal

26

12

(46.2)

3.09

(1.27, 7.51)

 

2.95

(0.87, 10.03)

 

3.54

(1.09, 11.43)

 

 Endocarditis

12

7

(58.3)

5.04

(1.47, 17.25)

 

17.43

(2.74, 111.06)

 

18.94

(3.45, 104.06)

 

 Bacteremia

5

0

(0.0)

0.00

(0.00, )

 

0.00

(0.00, )

 

0.00

(0.00, )

 

 CNS

4

1

(25.0)

1.20

(0.12, 12.04)

 

9.22

(0.71, 118.97)

 

7.66

(0.63, 93.73)

 

Microbiological samples

     

0.008

  

0.028

  

0.025

 Positive

129

24

(18.6)

1.00

Reference

 

1.00

Reference

 

1.00

Reference

 

 Negative

83

26

(31.3)

2.00

(1.05, 3.79)

 

3.58

(1.34, 9.55)

 

3.34

(1.29, 8.63)

 

 Not obtained

8

5

(62.5)

7.29

(1.63, 32.63)

 

2.91

(0.35, 24.09)

 

4.44

(0.60, 32.95)

 

Empirical antimicrobial agents

            

 Suspected focus of infection

     

0.433

      

  Appropriate compliance

171

38

(22.2)

1.00

Reference

       

  Inappropriate compliance

39

11

(28.2)

1.38

(0.63, 3.02)

       

 Confirmed focus of infection

     

0.027

  

0.241

   

  Appropriate

168

35

(21.0)

1.00

Reference

 

1.00

Reference

    

  Inappropriate

52

19

(36.5)

2.17

(1.10, 4.27)

 

0.79

(0.33, 1.91)

    

 Microbiological aetiologye

     

< 0.001

      

  Adequate

106

12

(11.3)

1.00

Reference

       

  Inadequate

23

12

(52.2)

8.55

(3.10, 23.58)

       

 In-hospital initial dose administered

     

0.002

  

0.051

  

0.046

  <6 hours after admission

157

30

(19.1)

1.00

Reference

 

1.00

Reference

 

1.00

Reference

 

  ≥6 hours after admission

54

22

(40.7)

2.91

(1.49, 5.71)

 

2.52

(1.00, 6.38)

 

2.48

(1.02, 6.02)

 

 Pre-hospital administration

     

0.059

  

0.055

  

0.041

  No

205

48

(23.4)

1.00

Reference

 

1.00

Reference

 

1.00

Reference

 

  Yes

15

7

(46.7)

2.86

(0.99, 8.30)

 

4.13

(0.99, 17.21)

 

4.20

(1.08, 16.39)

 
  1. Abbreviations: OR: odds ratio; CI: confidence interval.
  2. an = 220.
  3. bIncludes all categories with P < 0.10 in the unadjusted analyses; n = 211; Hosmer-Lemeshow’s chi-square = 12.38, df = 8, P = 0.135.
  4. cFrom backward stepwise selection at significance level 0.05; n = 211; Hosmer-Lemeshow’s chi-square = 3.18, df = 8, P = 0.923.
  5. dIncluding chronic kidney, liver and rheumatic diseases.
  6. eNot included in multivariate analysis due to a substantial number of not applicable cases (if included, significant in multivariate analysis).
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us